Rothschild Investment Corp Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Rothschild Investment Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 21, 2022	SELL	$144.95 - $152.29 $565,305 - $593,931	-3,900 Reduced 60.94%	2,500 $378,000
Q2 2022 Jul 12, 2022	SELL	$83.14 - $145.99 $315,932 - $554,762	-3,800 Reduced 37.25%	6,400 $933,000
Q1 2022 Apr 18, 2022	SELL	$110.08 - $142.92 $16,512 - $21,437	-150 Reduced 1.45%	10,200 $1.21 Million
Q4 2021 Jan 24, 2022	SELL	$99.73 - $148.48 $19,946 - $29,695	-200 Reduced 1.9%	10,350 $1.43 Million
Q3 2021 Oct 12, 2021	SELL	$98.85 - $138.91 $123,562 - $173,637	-1,250 Reduced 10.59%	10,550 $1.47 Million
Q2 2021 Jul 19, 2021	BUY	$65.78 - $105.02 $144,716 - $231,044	2,200 Added 22.92%	11,800 $1.15 Million
Q1 2021 Apr 15, 2021	BUY	$64.07 - $91.75 $288,314 - $412,875	4,500 Added 88.24%	9,600 $656,000
Q4 2020 Jan 25, 2021	BUY	$65.07 - $98.24 $331,856 - $501,024	5,100 New	5,100 $437,000
Q3 2020 Oct 22, 2020	SELL	$59.04 - $77.95 $165,312 - $218,260	-2,800 Closed	0 $0
Q2 2020 Jul 24, 2020	BUY	$29.01 - $74.23 $81,228 - $207,844	2,800 New	2,800 $205,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Rothschild Investment Corp , based on Form 13F filings with the SEC.

Stay updated on Rothschild Investment Corp with notifications on news.